TABLE 1.
Demographic, clinical, and laboratory findings of RA patients
| Number of the RA patients, n | 52 |
|---|---|
| Age, years | 51.7±13.0 |
| Female/male, n (%) | 48/4 (92.3/7.7) |
| BMI, kg/m2 | 28.9±5.0 |
| Disease duration, years | 13.8±7.2 |
| Follow-up time, months | 35.0±14.7 |
| Distributions of anti-TNF drugs, (%) | |
| Etanercept | 32.7 |
| Certolizumab | 23.1 |
| Adalimumab | 23.1 |
| Golimumab | 15.4 |
| Infliximab | 5.8 |
| Types of anti-TNF, (%) | |
| w/Fc | 76.9 |
| wo/Fc | 23.1 |
| Anti-TNF is first biologic drug, (%) | |
| Yes | 75.0 |
| No | 25.0 |
| Still on anti-TNF drug, (%) | |
| Yes | 55.8 |
| No | 44.2 |
| Duration of stay on the anti-TNF drugs, (%) | |
| ≤24 months | 30.8 |
| >24 months | 69.2 |
| CsDMARDs used with anti-TNF, (%) | |
| None | 23.0 |
| CsDMARD monotherapy | 63.5 |
| CsDMARD combination | 13.5 |
| MTX usage along with anti-TNF, (%) | |
| Yes | 48.1 |
| No | 51.9 |
| Steroid usage along with anti-TNF, n (%) | |
| Yes | 40.4 |
| No | 59.6 |
| RF titres, IU/mL | 58.1 (104.8) |
| RF, (%) | |
| ≤42 IU/mL | 46.2 |
| >42 IU/mL | 53.8 |
| Anti-CCP, (%) | |
| Positive | 69.2 |
| Negative | 30.8 |
| Comorbidities, (%) | |
| Yes | 50 |
| No | 50 |
| Number of comorbidity | 1 (2) |
| Smoking, n (%) | |
| Yes | 17.3 |
| No | 82.7 |
| Previous number of bDMARD | 1 (2) |
| Previous number of csDMARD | 3 (1) |
| Isoniazid prophylaxis, (%) | |
| Yes | 67.3 |
| No | 32.7 |
| NSAID usage, (%) | |
| Yes | 71.2 |
| No | 28.8 |
Continuous variables are presented as either mean±SD or median (IQR) according to normality. Categorical variables are given in percentage. BMI: Body mass index; bDMARD: Biological disease-modifying antirheumatic drug; csDMARD: Conventional synthetic disease-modifying antirheumatic drug; CCP: Cyclic citrullinated peptides; MTX: Methotrexate; NSAID: Nonsteroidal anti-inflammatory drug; RF: Rheumatoid factor; TNF: Tumor necrosis factor; w/Fc: With Fc; wo/Fc: Without Fc.